Elevated Metabolic Activity on18F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer.
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is deeply involved in the pathogenesis of lung cancer. We evaluated the metabolic characteristics of non-small cell lung cancer (NSCLC) in patients with and without expression of EZH2 using18F-fluorodeoxyglucose positron-emission tomography/ computed tomography (18F-FDG PET/CT).



The EZH2 protein expression of 268 patients with resected NSCLC, whose preoperative18F-FDG PET/CT information was available, was evaluated by immunohistochemistry with clone 6A10 antibody; cases with Allred score ≥3 were considered positive.



Maximized standard uptake values in cases of EZH2-positive NSCLC and adenocarcinoma were significantly higher in comparison to EZH2-negative cases (p<0.001, and p<0.001, respectively). The expression of EZH2 in NSCLC and adenocarcinoma was associated with significantly poorer survival.



In patients with NSCLC and adenocarcinoma, EZH2 positivity was associated with a high uptake of FDG, suggesting that EZH2 might define metabolically malignant lung cancer.
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan gouji104kawa@gmail.com.
Gouji
G
Toyokawa
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.|Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kazuki
K
Takada
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Tatsuro
T
Okamoto
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yuka
Y
Kozuma
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Taichi
T
Matsubara
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Naoki
N
Haratake
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takaki
T
Akamine
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Shinkichi
S
Takamori
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Masakazu
M
Katsura
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Fumihiro
F
Shoji
Division of Molecular Modification and Cancer Biology, National Cancer Center, Tokyo, Japan.
Ryuji
R
Hamamoto
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yoshinao
Y
Oda
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yoshihiko
Y
Maehara
D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000378:metabolism; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000378:metabolism; D018572:Disease-Free Survival; D000071221:Enhancer of Zeste Homolog 2 Protein / Q000235:genetics* / Q000378:metabolism; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000737:chemistry*; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D000072078:Positron Emission Tomography Computed Tomography; D012372:ROC Curve; D016896:Treatment Outcome
D019788:Fluorodeoxyglucose F18; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein
EZH2; PET/computed tomographic; SUVmax; lung cancer